Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Dimitrios Patoulias and Michael Doumas.
Connection Strength

10.061
  1. Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies. Endocrinol Metab (Seoul). 2021 08; 36(4):904-908.
    View in: PubMed
    Score: 0.959
  2. Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors? Kardiol Pol. 2021; 79(9):1048-1049.
    View in: PubMed
    Score: 0.958
  3. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic. Diabetes Obes Metab. 2021 Jul; 23(7):1696-1700.
    View in: PubMed
    Score: 0.934
  4. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend? Pol Arch Intern Med. 2020 10 29; 130(10):922.
    View in: PubMed
    Score: 0.911
  5. Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. Diabetes Ther. 2020 Dec; 11(12):3003-3005.
    View in: PubMed
    Score: 0.908
  6. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. Curr Hypertens Rep. 2020 09 10; 22(11):90.
    View in: PubMed
    Score: 0.902
  7. Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations. Acta Diabetol. 2021 01; 58(1):125-126.
    View in: PubMed
    Score: 0.898
  8. Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Pol Arch Intern Med. 2019 09 30; 129(9):648-649.
    View in: PubMed
    Score: 0.845
  9. Time to rethink the role of sodium-glucose co-transporter 2 inhibitors in the elderly. Pol Arch Intern Med. 2019 Feb 28; 129(2):143-144.
    View in: PubMed
    Score: 0.811
  10. SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. Curr Clin Pharmacol. 2018; 13(4):261-272.
    View in: PubMed
    Score: 0.749
  11. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021 Nov; 40(11):4671-4674.
    View in: PubMed
    Score: 0.241
  12. COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute? J Hum Hypertens. 2020 11; 34(11):764-767.
    View in: PubMed
    Score: 0.223
  13. COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. Eur J Intern Med. 2020 Jul; 77:153-155.
    View in: PubMed
    Score: 0.221
  14. Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. J Sex Med. 2019 08; 16(8):1199-1211.
    View in: PubMed
    Score: 0.206
  15. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. Curr Pharm Des. 2018; 24(31):3638-3646.
    View in: PubMed
    Score: 0.187
  16. Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. SN Compr Clin Med. 2020; 2(9):1419-1429.
    View in: PubMed
    Score: 0.056
  17. Evaluation, risk stratification and management of hypertensive patients in the perioperative period. Eur J Intern Med. 2019 Nov; 69:1-7.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.